-transparent.png){kind=logo}
Seven patients with rapidly cycling, lithium-resistant affective illness were followed for an average of 1.7 years during prophylactic treatment with carbamazepine administered on either a blind or an open basis. The number of manic and depressive episodes per year decreased significantly--from 16.4 before treatment to 5.6 during carbamazepine treatment; severity and duration of episodes were also reduced. Six of seven patients relapsed after carbamazepine dose reduction or discontinuation. These preliminary data add further support to the growing evidence that carbamazepine may be useful in the acute and prophylactic treatment of some lithium-resistant patients.
Related Publications
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
July 1980,
The American journal of psychiatry,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
January 1983,
Indian journal of psychiatry,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
September 1994,
The American journal of psychiatry,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
January 1981,
Psychopharmacology,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
January 1973,
Folia psychiatrica et neurologica japonica,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
November 1986,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
March 1985,
East African medical journal,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
January 1995,
Psychopathology,
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
December 1984,
Lancet (London, England),
R M Post, and
T W Uhde, and
J C Ballenger, and
K M Squillace
August 1986,
Lancet (London, England),
